CN108300729A - Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application - Google Patents
Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application Download PDFInfo
- Publication number
- CN108300729A CN108300729A CN201810107622.2A CN201810107622A CN108300729A CN 108300729 A CN108300729 A CN 108300729A CN 201810107622 A CN201810107622 A CN 201810107622A CN 108300729 A CN108300729 A CN 108300729A
- Authority
- CN
- China
- Prior art keywords
- human cytomegalovirus
- genetic engineering
- genes
- engineering bacterium
- containing human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150074433 UL124 gene Proteins 0.000 title claims abstract description 81
- 241000894006 Bacteria Species 0.000 title claims abstract description 59
- 239000013612 plasmid Substances 0.000 title claims abstract description 58
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 51
- 238000010353 genetic engineering Methods 0.000 title claims abstract description 21
- 238000005215 recombination Methods 0.000 claims abstract description 18
- 230000006798 recombination Effects 0.000 claims abstract description 18
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 13
- 241001597008 Nomeidae Species 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 abstract description 10
- 108020001507 fusion proteins Proteins 0.000 abstract description 10
- 230000009465 prokaryotic expression Effects 0.000 abstract description 4
- 239000013613 expression plasmid Substances 0.000 abstract description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract description 2
- 230000003950 pathogenic mechanism Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- 230000029087 digestion Effects 0.000 description 25
- 230000009182 swimming Effects 0.000 description 21
- 239000000499 gel Substances 0.000 description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 229960001866 silicon dioxide Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000003292 glue Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012154 double-distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000032420 Latent Infection Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- PXAFZDXYEIIUTF-LKTVYLICSA-N Ala-Trp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O PXAFZDXYEIIUTF-LKTVYLICSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- CRNKLABLTICXDV-GUBZILKMSA-N Asp-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N CRNKLABLTICXDV-GUBZILKMSA-N 0.000 description 1
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- GMGKDVVBSVVKCT-NUMRIWBASA-N Gln-Asn-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GMGKDVVBSVVKCT-NUMRIWBASA-N 0.000 description 1
- SMLDOQHTOAAFJQ-WDSKDSINSA-N Gln-Gly-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SMLDOQHTOAAFJQ-WDSKDSINSA-N 0.000 description 1
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- VPFGPKIWSDVTOY-SRVKXCTJSA-N Pro-Glu-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O VPFGPKIWSDVTOY-SRVKXCTJSA-N 0.000 description 1
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 1
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical group C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
The invention discloses a kind of recombinant plasmid containing human cytomegalovirus UL124 genes, genetic engineering bacterium and its applications.The recombinant plasmid for containing human cytomegalovirus UL124 genes is obtained by the way that human cytomegalovirus UL124 genes to be inserted into expression plasmid pET32a.Then the prokaryotic expression engineering bacteria of the fusion protein with histidine tag can be expressed by it being rotated into structure in Escherichia coli by heat, which can express corresponding fusion protein.The genetic engineering bacterium for containing human cytomegalovirus UL124 gene recombination plasmids provides raw material for human cytomegalovirus UL124 polyclonal antibodies and monoclonal antibody preparation, simultaneously also be further research UL124 genes concrete function lay the foundation, to for disclose HCMV infection and pathogenic mechanism and treat direction is provided.
Description
Technical field
The present invention relates to field of biology, more particularly to a kind of recombinant plasmid containing human cytomegalovirus UL124 genes,
Genetic engineering bacterium and its application.
Background technology
Human cytomegalovirus (human cytomegalovirus, HCMV) is also known as cells inclusions virus, due to infection
Cell enlargement, and there is huge intranuclear inclusion, it is therefore named, belong to Betaherpesvirdae, is known maximum DNA blister sores
Poison is a kind of opportunistic virion of wide-scale distribution and the important teratogenesis of the mankind, causes neurotrosis pathogen.HCMV is certainly
Infect very universal in right crowd, higher in crowd infection rate, the infection rate of developed country is 30~70%.
The infection for the first time of HCMV mostly occurs in infant period.HCMV once invades human body, will be long-term or be present in all the life
In vivo, for the normal individual of most immune functions, often it is presented without the latent infection of clinical symptoms;Immune
Severe infections can occur in the incomplete baby of systematic growth and immune deficiency person and lethal can die.For pregnant women and youngster
The clinical symptoms of child, HCMV infection are more serious, and antenatal merging HCMV acute infections easily lead to fetal abortion, premature labor and abnormal
Shape.
It is found in the experiment studied in vitro:Many HCMV genes be for the viral proliferation of itself it is dispensable, because
This infer these genes be mainly with virus tissue tropisms, immunologic escape, it is pathogenic, send out, optimizes growth or hide
It infects related.
Human cytomegalovirus UL124 genes sequence in HCMV is conservative, and bioinformatic analysis shows that the gene is compiled
One transmembrane protein of code.NB, which is tested, detects the transcription product of UL124, after knocking out UL124, HCMV grown in HFF by
It seriously undermines, while UL124 is also the relevant transcript of hiding now known related with HCMV latent infection hematopoietic progenitor cells
One of.These experimental results and bioinformatic analysis all show that UL124 is extremely important to the infection of HCMV and increment, need into
The research of one step.Therefore, the engineering bacteria of human cytomegalovirus UL124 gene recombination plasmids is built, can be to prepare corresponding antibody
It lays the first stone, while being also that the further concrete function for studying UL124 genes lays the foundation, to be the infection for disclosing HCMV
Being there is provided with pathogenic mechanism and treatment may.
Invention content
The primary purpose of the present invention is that the shortcomings that overcoming the prior art and deficiency, provide one kind and containing human cytomegalovirus
The recombinant plasmid of UL124 genes.
Another object of the present invention is to provide the gene works containing above-mentioned human cytomegalovirus UL124 gene recombination plasmids
Journey bacterium.
Another object of the present invention is to provide the above-mentioned genetic engineering containing cytomegalovirus UL124 gene recombination plasmids
The application of bacterium.
The purpose of the invention is achieved by the following technical solution:A kind of recombination containing human cytomegalovirus UL124 genes
Plasmid contains UL124 genetic fragments, wherein the nucleotide sequence of UL124 genetic fragments such as SEQ ID No:Shown in 1.
The construction method of the recombinant plasmid containing human cytomegalovirus UL124 genes by conventional method will
UL124 genetic fragments are inserted into pET32a plasmids and obtain.
A kind of genetic engineering bacterium containing human cytomegalovirus UL124 gene recombination plasmids, conversion have above-mentioned huge containing someone
The recombinant plasmid of cell virus UL124 genes.
The construction method of the genetic engineering bacterium containing human cytomegalovirus UL124 gene recombination plasmids, for will be upper
The recombinant plasmid transformed containing human cytomegalovirus UL124 genes is stated to enter in prokaryotic expression engineering bacteria.
The genetic engineering bacterium is preferably Escherichia coli;More preferably bacillus coli DH 5 alpha or BL21 (DE3).
The genetic engineering bacterium containing human cytomegalovirus UL124 gene recombination plasmids is in UL124 recombinant protein systems
Application in standby.
A kind of preparation method of UL124 recombinant proteins, by above-mentioned containing human cytomegalovirus UL124 gene recombination plasmids
Genetic engineering bacterium passes through activation culture and fermented and cultured, adds derivant IPTG and carries out induced expression, obtains UL124 and recombinates egg
In vain;Preferably:Above-mentioned engineering bacteria is seeded in the LB liquid medium containing ampicillin (Amp) resistance and carries out activation training
Support, be then transferred to containing fermented and cultured is carried out in amicillin resistance LB liquid medium, add derivant IPTG into
Row induced expression obtains UL124 recombinant proteins.
The condition of the induced expression is preferably:30 DEG C of induction 6h.
The working concentration of the IPTG is 0.5mM/L.
The preparation method of the UL124 recombinant proteins further includes that the UL124 recombinant proteins of acquisition are purified and determined
The step of amount:UL124 recombinant proteins are first passed through into nickel column separating purification, BCA methods is then reused and UL124 after purification is recombinated
Albumen is quantified.
The genetic engineering bacterium containing human cytomegalovirus UL124 gene recombination plasmids is preparing human cytomegalovirus
Application in UL124 protein polyclone antibodies;The engineering bacteria can give expression to the fusion protein with histidine tag.
The present invention has the following advantages and effects with respect to the prior art:The present invention provides one kind containing human cytomegalovirus
The engineering bacteria of viral UL124 gene recombination plasmids, by the way that human cytomegalovirus UL124 genes to be inserted into expression plasmid pET32a
Recombinant plasmid pET32a-UL124 is obtained, rotates into e. coli bl21 (DE3) to construct to express later by heat and carries
The prokaryotic expression engineering bacteria of the fusion protein of histidine tag, the bacterial strain can express corresponding fusion protein, which can
To carry out related immunological experiment as antigen, the engineering bacteria of human cytomegalovirus UL124 gene recombination plasmids can be other
The structure of the engineering bacteria of related gene recombinant plasmid provides experiment experience, and research is resisted on the material and strategy of human cytomegalovirus
More thinking points again.Importantly, providing original for human cytomegalovirus UL124 polyclonal antibodies and monoclonal antibody preparation
Material, while being also that the further concrete function for studying UL124 genes lays the foundation, to be the infection and cause for disclosing HCMV
Interpretation of the cause, onset and process of an illness system and treatment provide direction.
Description of the drawings
Fig. 1 is the organigram of recombinant plasmid.
Fig. 2 is UL124PCR amplified production electrophoresis schematic diagrames;Wherein, swimming lane M is DNAmarker;Swimming lane 1 and 2 is
UL124PCR amplified productions.
Fig. 3 is pET32a electrophoresis result figures;Wherein, figure A and B is the pET32a after pET32a and double digestion;Swimming lane M is
DL5000DNAMarker;It is pET32a (5900bp) to scheme swimming lane 1 and 2 in A;It is pET32a double digestions to scheme swimming lane 1 and 2 in B.
Fig. 4 is bacterium colony PCR and extraction plasmid double digestion electrophoresis schematic diagram.Wherein, figure A is the bacterium colony converted after attachment
PCR;Figure B is the double digestion qualification result for extracting plasmid;Swimming lane M is DL2000DNA Marker;Swimming lane 1 and 2 is in figure A
UL124 bacterium colonies PCR (459bp);Swimming lane 1 and 2 is the double digestion qualification result for extracting plasmid in figure B.
Fig. 5 is the optimum results figure of induced expression condition;Wherein, figure A is the optimum results of induced expression temperature, swimming lane M
For albumen Marker, swimming lane 1 is to be not added with derivant, and swimming lane 2,3,4,5 is respectively 16 DEG C, 20 DEG C, 30 DEG C, 37 DEG C of inducing temperature
(IPTG concentration 0.5mmol/L, induction time 6h);Scheme the optimum results that B is induced expression IPTG concentration, swimming lane M is albumen
Marker, swimming lane 1 are to be not added with derivant, the respectively IPTG concentration 0.1mmol/L, 0.3mmol/L of swimming lane 2,3,4,5,6,7,
0.5mmol/L, 0.8mmol/L, 1.0mmol/L, 1.5mmol/L (30 DEG C of inducing temperature, induction time 6h);It is induction to scheme C
The optimum results of expression time, swimming lane M are albumen Marker, and swimming lane 7 is to be not added with derivant, and swimming lane 1,2,3,4,5,6 is respectively
Induction time 12h, 10h, 8h, 6h, 4h, 2h (IPTG concentration 0.5mmol/L, 30 DEG C of inducing temperature).
Fig. 6 is purifying schematic diagram and the fusion of the expression bacterium expressed fusion protein containing recombinant plasmid pET32a-UL124
The Western blot result figures of albumen;Wherein, figure A is the expression bacterium expression fusion egg containing recombinant plasmid pET32a-UL124
White purifying schematic diagram, each swimming lane (swimming lane 1~8) from left to right indicate albumen Marker, are pierced by, 25mmol/L imidazoles respectively
Eluent, 100mmol/L imidazole elutions, 150mmol/L imidazole elutions, 200mmol/L imidazole elutions, 500mmol/L
Imidazole elution, 500mmol/L imidazole elutions;Scheme the Western blot result figures that B is fusion protein;Swimming lane M is albumen
Marker;Swimming lane 1 is the total bacterial protein for being not added with derivant in figure B, and 2 be UL124 fusion proteins.
Specific implementation mode
With reference to embodiment, the present invention is described in further detail, and embodiments of the present invention are not limited thereto.
Embodiment 1
One, plasmid construction
(1) UL124 gene primers design
According to the sequence of UL124 genes in TB40/E (KF297339.1) the Strain genome announced on GenBank, entirely
Long 459bp (gene order such as SEQ ID No:Shown in 1;Its protein translation product such as SEQ ID No:Shown in 2), be with the sequence
Template, it is soft using Primer Select with PET32a plasmids (excellent precious biological Co., Ltd) for cloned plasmids and expression plasmid
Part chooses suitable restriction enzyme site and carries out design of primers.Designed primer such as following table:
1 UL124 design of primers tables of table
Note:F (sense primer);R (downstream primer).
(2) UL124 gene PCRs
According to the gene order (GenBank for the HCMV TB40/E-BAC being published on GenBank:EF999921.1,
Quote article (Cloning and sequencing of a highly productice, endotheliotropic virus
Strain derived from human cytomegalovirus TB40/E)) it is template, it is carried out in following reaction system
PCR:
2 PCR reaction system tables of table
PCR amplification condition see the table below:
Table is arranged in 3 PCR reaction conditions of table
Take 5 μ l of PCR product into row agarose gel electrophoresis, according to glue interpretation of result is run, if band specificity is very high,
It can use PCR product purification kit recovery product that must terminate PCR product whole loading electrophoresis, electrophoresis if having miscellaneous band appearance
Afterwards, adhesive tape of corresponding size is cut according to Maker, is recycled using omega plastic recovery kits.
Two, UL124 genes agarose gel electrophoresis
1, according to the size of the target DNA fragment expanded, the Ago-Gel of suitable concentration is selected;UL124 genes are complete
Long 459bp base-pairs select 1% Ago-Gel;
2, agarose powder 0.2g is weighed, the 1 × TAE buffer solution 20mL for preparing and having diluted in advance are added, are put in microwave
In stove, moderate heat heats 2min;
3, when the gel room temperature melted is cooled to 60 DEG C or so, the GelStain of 0.2 μ l is added thereto, fully shakes up
It slowly pours into and is plugged in the glue groove of comb in advance afterwards, bubble is avoided to generate, after being stored at room temperature about 30min, gel can coagulate completely
Gu glue is completed;
4, start before running glue, gently pull up comb from vertical direction, gel is put into electrophoresis tank, ensure the leaching of electrophoresis liquid energy
Do not have monoblock glue, after placing steadily, glue can be run by the sequence point sample finished in advance;
5, after point sample, according to target DNA size and gel strength, electrophoretic parameters are set as:Electric current 200mA, time
45min (runs glue to adjust according to the position of bromophenol blue and run the glue time in the process);
6, after completing electrophoresis, gel is taken out from electrophoresis tank, and electrophoresis liquid is filtered dry, be put in preprepared preservative film
On, it is placed into gel imager, adjusts suitable angle, take pictures, analyze and preserve result (Fig. 2).
Three, UL124 genes gel recycles
1, it after vertical agarose gel electrophoresis, moves in dark place, under ultra violet lamp, according to Maker and purpose
Mrna length cuts the Ago-Gel containing target DNA with clean blade;
When 2, cutting target DNA, as possible precisely, the extra gel except target DNA band is cut less, it is suitable by what is cut
When the EP that the gel piece of size is put into a sterile 1.5ml of preprepared manages (having weighed), after weighing, calculation takes gel
Net weight, the addition XP2 solution of equal proportion volume;
3, the EP pipes of the 1.5ml for the gel piece for being mixed with XP2 solution are placed in water-bath, 57 DEG C of heating, every 2~3min
Reverse mixing, until gel piece melts completely;
Its mediation mixing and of short duration centrifugation, can finally be added into advance by 4, the gel cooling after complete melt
Assembled silicagel column, room temperature, 10000 × g centrifuge 1min, topple over the waste liquid in collecting pipe;
5, it adds in 300 μ l XP2 solution to silicagel column, after room temperature 10000 × g centrifugations 1min, by the liquid in collecting pipe
Body is outwelled;
6, it washs solution with 700 μ l SPW and washs silicagel column, 10000 × g of room temperature centrifuges 1min, by the liquid in collecting pipe
It outwells;
7, it is primary that 6 steps are repeated;
8, sky gets rid of silicagel column, and 12000 × g of room temperature centrifuges 2min, removes extra SPW washing solution;
9, it takes out silicagel column and puts it into the 1.5mL EP pipes of sterilizing, after being placed at room temperature for 2min, into silicagel column
30 μ l are added and have been heated to 65 DEG C of sterile ddH20 in advance, after being stored at room temperature 1min, 12000 × g centrifuges 1min, and taking-up has been discarded
Silicagel column, the liquid collected in EP pipes is target DNA solution;
10, the target DNA concentration and purity of detection recycling, sample are put in -20 DEG C of preservations.
Four, pET32a plasmid extractions
1, the plasmid evening before yesterday is taken out, the DH5 α strains containing pET32a plasmids is taken out from -20 DEG C of refrigerators, draws 4 μ l, be inoculated in and contain
In the 4mL LB liquid mediums of ampicillin (final concentration of 100 μ g/ml), 220rpm/min cultures 12 in 37 DEG C of incubators
~16h;
2, second day, take out the bacterium solution that has been incubated overnight, and thalline is added in 1.5mL EP pipes, 12000 × g room temperatures from
Heart 1min abandons supernatant, repeats step, 4mL bacterium solutions are all collected into 1.5mL EP pipes;
3, it exhausts after extra supernatant, adds in 250 μ l solution I to EP pipes, it is heavy that thalline is gently blown and beaten with pipettor
It forms sediment, after thalline resuspension, is put on the rotary vibrator of whirlpool, makes its complete mixing;
4,250 μ l solution II are added, for several times, the reverse time will be got hold of the mixing that lightly turns upside down, control
System is between 2min~5min, and after having overturned, liquid generally can transparent clarification;
5, be eventually adding 350 μ l solution III, the mixing that lightly turns upside down for several times, until there is white precipitate to be formed,
Reverse mixing number cannot be excessive, is and then put in compact centrifuge, room temperature, and 13000 × g centrifuges 10min;
6, after centrifuging, liquid-transfering gun is transferred to supernatant in marked good silicagel column, silicagel column puts 2ml's into
In centrifuge tube, white depositions are not sucked in silicagel column, are put in compact centrifuge, 10000 × g of room temperature, centrifuges 1min;
7, the waste liquid in collecting pipe is outwelled, 500 μ l HB solution is drawn, is added in silicagel column, room temperature 10000 × g centrifugations
1min;
8, the waste liquid in collecting pipe is outwelled, adds in 700 μ l DNAWash Buffer to silicagel column, (first checks DNAWash
Whether Buffer has been added absolute ethyl alcohol) room temperature 10000 × g centrifugations 1min;
9, it is primary that 8 steps are repeated;
10, sky gets rid of silicagel column, and 13000 × g of room temperature centrifuges 2min, removes extra DNAWash Buffer;
11, it takes out silicagel column to put it into the 1.5mL EP pipes of sterilizing, 50 μ l is added into silicagel column and have added in advance
Heat is to 65 DEG C of sterile ddH20, and after being stored at room temperature 1~2min, 12000 × g centrifuges 1min, takes out obsolete silicagel column, EP pipes
Middle liquid is target DNA solution;
12,1 μ l sample detections are taken to extract the concentration and purity of plasmid, remaining sample is for subsequent experimental or is put in -20
DEG C preserve.
Five, double digestion
1, UL124PCR products double digestion system such as following table:
4 PCR product double digestion system table of table
Ingredient | Volume (total 20 μ l) |
UL124PCR products | 10μl |
10×FastDigest buffer | 2μl |
FastDigest BamHI | 1μl |
FastDigest HindIII | 1μl |
ddH2O | 6μl |
Note:Endonuclease reaction condition:Digestion 50min in 37 DEG C of thermostat water baths;Control digestion system DNA total amounts are less than or wait
In 1 μ g.
2, it needs to be purified after completing endonuclease reaction.
3, pET32a plasmids double digestion system such as following table:
5 pET32a plasmid double digestion system tables of table
Note:Endonuclease reaction condition:Digestion 50min in 37 DEG C of thermostat water baths;Control digestion system plasmid total amount be less than or
Equal to 1 μ g.
4, it needs to be purified after completing endonuclease reaction.
Six, Product Purification Kit recycles double digestion product
1,4~5 times of combination liquid CP is added according to double digestion system, mixes well;
2, previous step acquired solution is added in adsorption column EC, is placed at room temperature for 1min, 10000 × g, centrifuged 1min, outwell
Waste liquid in collecting pipe;
3,700 μ l rinsing liquids WB (first check whether and absolute ethyl alcohol has been added), 10000 × g are added, centrifuges 1min, discards
Waste liquid;
4, it is primary that 3 steps are repeated;
5, adsorption column EC is put back in collecting pipe, 10000 × g, centrifuges 1min, removes rinsing liquid as far as possible, in order to avoid residual
Ethyl alcohol inhibits downstream reaction;
6, adsorption column is taken out, is put into a clean centrifuge tube, adds 30 μ l elution buffers at the intermediate position of adsorbed film
Liquid EB (heating effect is more preferable in 65~70 DEG C of water-baths in advance for elution buffer) is placed at room temperature for 2min, 13000 × g centrifugations
1min.If necessary to more amount DNA, obtained solution can be rejoined in adsorption column, centrifuge 1min.Take out obsolete silicon
Rubber column gel column, the liquid collected in EP pipes is target DNA solution;
7, the target DNA concentration and purity of detection recycling, to be preferably used for subsequent experimental.Sample is put in -20 DEG C of preservations.
Experimental result is as shown in Figure 3, wherein figure A and B is the pET32a after pET32a and double digestion.
Seven, UL124 double digestions recovery product connect reaction with pET32a plasmid double digestion recovery products
Coupled reaction system such as following table:
6 coupled reaction system table of table
Ingredient | Volume (total 10 μ l) |
PET32a plasmids | 5μl |
UL124 | 2μl |
10×T4Ligation Buffer | 2μl |
T4DNA Ligase | 1μl |
ddH2O | 0μl |
Connection reaction condition is to be placed in connection 16h or more in 16 DEG C of connection instrument, obtains recombinant plasmid.
Eight, the preparation of bacillus coli DH 5 alpha competent cell
1, it one lives:The unloaded strain DH5 α preserved with the activation of LB culture mediums, by volume 1:100 are inoculated with, 37 DEG C of perseverances
Warm shaking table 220rpm/min activates 12~16h;
2, it two lives:Strain DH5 α after being lived with LB culture mediums activation one, by volume 1:100 are inoculated with, 37 DEG C of constant temperature
Shaking table 220rpm/min activation makes OD600 values be 0.4~0.6;
3, take the bacterium solution 1ml after two work in being placed in ice bath 10min on ice in EP pipes, according to actual needs prepared by quantity;
4,4 DEG C, 4000 × g, most supernatant is abandoned as far as possible after centrifuging 5min;
2, the CaCl of the 1ml 0.1M that ice bath (30min) has been crossed is added2Thalline, then ice bath 30min is resuspended;
6, it 4 DEG C, 4000 × g, centrifuges and abandons most supernatant as far as possible after 5min (dried filter paper will be remaining after can using sterilizing
Liquid exhausts);
7, the CaCl of 50 μ l 0.1M is added2Thalline is resuspended, can be used after ice bath 0.5h, this is the DH5 α prepared
Competent cell;
8, the competence bacteria DH5 α prepared -20 DEG C are placed on to freeze and (used in one month).
Nine, it converts
1, volume aspirated is that the connection liquid of 5 μ l is added in the DH5 α competent cells of the 50 μ l prepared in advance, gently
Mixing is positioned on ice, ice bath 30min;
2, it after the completion of waiting for ice bath, will be put in 42 DEG C of preheated in advance thermostat water baths added with the competence of connection liquid,
Heat shock 90s;
3, after completing heat shock, immediately competence is positioned on ice, ice bath 2min;
4, after ice bath 2min, the LB liquid medium of 900 μ l room temperatures is added into every EP pipe,
37 DEG C of constant-temperature shaking incubator concussions are put in, rotating speed 180rpm/min cultivates 45min;
5, cultured bacterium is put in centrifuge, room temperature, 3000 × g, time 60s after centrifugation, carefully inhales
700 μ l supernatants are removed, about 100 μ l culture mediums are stayed, thalline is resuspended;
6, the thalline for drawing 100 μ l is coated on and pre-prepared has added ampicillin (final concentration of 100 μ g/ml) anti-
Property LB tablets on, be placed in 37 DEG C of constant incubators, after just setting 15min, wait for that bacterium solution is absorbed completely, be inverted culture, culture
Time is 12~16h.
Ten, bacterium colony PCR is identified
1, it from 2 monoclonal colonies of picking on the LB tablets of the amicillin resistance with monoclonal, is inoculated into respectively
In 4ml LB liquid mediums containing ampicillin, 37 DEG C, rotating speed 220rpm/min, isothermal vibration incubator culture, training
It is 12~16h to support the time;
2, from cultured bacterium solution, masterplates of the 5 μ l as bacterium colony PCR is drawn, PCR amplification identification, specific body are carried out
System see the table below:
7 bacterium colony PCR reaction system tables of table
Reagent name | Volume (total 25 μ l) |
Sterile ddH2O | 13.25μl |
10×PCR buffer(with Mg2+) | 2.5μl |
dNTP | 2μl |
Bacterium solution template | 5μl |
Sense primer | 1μl |
Downstream primer | 1μl |
TaKaRa Taq | 0.25μl |
PCR amplification condition see the table below:
Table is arranged in 8 bacterium colony PCR reaction conditions of table
3, after PCR amplification, reaction product runs 1% agarose gel electrophoresis, and gel imager is taken pictures, and analyze,
Preserve experimental result.Experimental result is as shown in Figure 4 A.
11, double digestion is identified
1, according to the qualification result of bacterium colony PCR, the bacterium solution of target DNA fragment size will be amplified, carries out conservation, conservation
Method be total volume 1ml, bacterium solution 750 μ l, 100% 250 μ l of glycerine, mixing place -20 DEG C of preservations, and remaining bacterium solution is equal
It is used for extract plasmid;
2, the recombinant plasmid for obtaining extracting carries out double digestion identification, and reaction system see the table below:
9 recombinant plasmid double digestion reaction system table of table
Ingredient | Volume (total 20 μ l) |
PET32a plasmids (contain Insert Fragment) | 10μl |
10×FastDigest buffer | 2μl |
FastDigest BamHI | 1μl |
FastDigest HindIII | 1μl |
ddH2O | 6μl |
Note:Endonuclease reaction condition:Digestion 50min in 37 DEG C of thermostat water baths.
3,1% Ago-Gel is run after double digestion, is taken pictures, and result is analyzed and preserve.Experimental result is as shown in Figure 4 B.
12, Plasmid samples are sequenced
Company is sent to be sequenced the Plasmid samples that can go out target gene size segment with double digestion, it, will after sequencing result comes out
Sequencing result is compared with the gene order above GennBank using BLAST, analyses and comparison result.If sequencing result with
Download sequence mismatches, and repeats the above experiment until sequencing result matches.
13, (method refers to the 8th " system of bacillus coli DH 5 alpha competent cell for the preparation of competence bacteria BL21 (DE3)
It is standby ").
14, pET32a (UL124) conversion expression bacterium BL21 (DE3) (method refers to the 9th " conversion ").
15, the prokaryotic expression (DH5 α) of UL124 recombinant proteins
(1) UL124 recombinant protein expression quantity is tested in different temperatures culture
1, experiment is provided with 16 DEG C, and 20 DEG C, 30 DEG C, 37 DEG C of 4 temperature are expressed, and volume of culture condition setting is:4ml
Liquid LB Tube propagations, final concentration 0.5mmol/L, the induction time 6h of IPTG.
2, above expression thalline 1ml, 10000 × g are collected, most supernatant is abandoned as far as possible after centrifuging 1min, is separately added into 60 μ l
1 × SDS-PAGE Loading Buffer, with liquid-transfering gun blow and beat mixing, after 100 DEG C of the above sample boils 10min, -20 DEG C
Preserve or run the analysis of SDS-PAGE protein adhesives;
3, after the analysis of SDS-PAGE protein adhesives, the best 30 DEG C of conducts of temperature of expression effect in above 4 temperature are determined
Express temperature (Fig. 5 A).
(2) various concentration IPTG expresses UL124 recombinant proteins and tests
The experiment is carried out using the inducing temperature of the above single factor experiment, setting IPTG induced concentrations are:0mM/L,
0.1mM/L, 0.3mM/L, 0.5mM/L, 0.8mM/L, 1.0mM/L, 1.5mM/L, 4ml liquid LB Tube propagations are expressed, induction temperature
30 DEG C of degree, induction time 6h.
Most supernatant is abandoned as far as possible after collecting above expression thalline 1ml, 10000 × g centrifugation 1min, is separately added into the 1 of 60 μ l
× SDS-PAGE Loading Buffer blow and beat mixing with liquid-transfering gun, after 100 DEG C of the above sample boils 10min, -20 DEG C of preservations
Or run the analysis of SDS-PAGE protein adhesives.According to experimental result, determine that the above various concentration derivant IPTG expression effects are best
Concentration 0.5mM/L be derivant best induced concentration (Fig. 5 B).
(3) experiment of the different incubation times to UL124 recombinant protein expression quantity
1, the experiment being carried out using the inducing temperature of the above single factor experiment and inducer concentrations, 2h, 4h is arranged in experiment,
Totally 6 time points collect thalline by 6h, 8h, 10h, 12h;4ml liquid LB Tube propagations are expressed, IPTG concentration 0.5mmol/L, induction
30 DEG C of temperature.
2, above expression thalline 1ml, 10000 × g are collected respectively, are abandoned most supernatant as far as possible after centrifuging 10min, are separately added into
1 × SDS-PAGE Loading Buffer of 60 μ l blow and beat mixing with liquid-transfering gun, after 100 DEG C of the above sample boils 10min ,-
20 DEG C preserve or run the analysis of SDS-PAGE protein adhesives.
3, after the analysis of SDS-PAGE protein adhesives, the best induction expression protein acquisition time point in above 6 times is determined
For 6h (Fig. 5 C).
16, UL124 recombinant proteins are collected
1, it determines that expression temperature, inducer concentrations collect the thalline time according to the above experiment, expands the expression body of expression bacterium
Product collects thalline, and 4 DEG C, 10000 × g abandons most supernatant as far as possible after centrifuging 10min;
2, thalline is resuspended in 1 × PBS buffer solution that (1/20 cell growth volume) is added, and 4 DEG C, 10000 × g, centrifuges 10min
Most supernatant is abandoned as far as possible;
3, precipitation is added 1 × PBS buffer solution and thalline is resuspended, and carrying out ice-bath ultrasonic wave using sonicator breaks bacterium, breaks
Bacterium parameter is set as:150W, work 4s, stops 6s, is crushed about 30min, until bacterium solution becomes clarification;
4,10000 × g, centrifuges 30min by 4 DEG C, and supernatant, precipitation is gone to be resuspended and washed with 1 × PBS buffer solution, 10000 × g, and 4
DEG C, 30min is centrifuged, supernatant is removed.
5, urea liquid of the precipitation containing 8mol/l dissolves 1h, centrifuges to obtain supernatant again, with 0.22 μm of membrane filtration, into
Row protein purification.
17, the isolation and purification of recombinant protein
1, Ni columns are cleaned with the deionized water of 10 times of column volumes (0.22 μm of membrane filtration);
2, pillar is balanced with the 5mmol/l imidazole buffers (containing 8mol/l urea) of 5 times of column volumes;
3, loading, coutroi velocity are pierced by liquid in 1ml/min or so, collection, are analyzed for SDS/PAGE protein adhesives;
4, contain 20mmol/l, 100mmol/l, 150mmol/l, 200mmol/l, 500mmol/l with 5 times of column volumes respectively
The buffer solution of imidazoles elutes, and flow control collects eluent in 2ml/min, and the eluent that keeps sample respectively is for SDS/PAGE points
Analyse the distribution situation of protein.
Experimental result:Containing recombinant vector pET32a-UL124 expression bacterium expressed fusion protein purifying schematic diagram and
The results are shown in Figure 6 by the Western blot of fusion protein.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, it is other it is any without departing from the spirit and principles of the present invention made by changes, modifications, substitutions, combinations, simplifications,
Equivalent substitute mode is should be, is included within the scope of the present invention.
Sequence table
<110>Ji'nan University
<120>Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 459
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<220>
<223>UL124 genes
<400> 1
atggaaagga acagtctgtt agtctgtcag ctattatgtc tggtggcgcg cgcggcagca 60
acgagtactg ctcagactac actgccctcc accgttaaca gcaccgcaac gggagttacc 120
tctgactctt atcagaacac aacaactcag ctgcctgcat cttcttctgc cgctgcctta 180
agtcttccaa atgcgtcagc ggtgcaagcc cgctccccga gctcattttc agacacatac 240
cctaccgcca cggccttgtg cggcacactg gtggtggtgg gcatcgtgct gtgcctaagt 300
ctggcctcca ctgttaggag caaggagctg ccaagcgacc atgagccgct ggaggcatgg 360
gagcagggct cggatgtaga agctccgccg ctaccggaga agagcccatg tccggaacac 420
gtacccgaga ttcgcgtgga gatcccacgc tatgtttaa 459
<210> 2
<211> 152
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<220>
<223>UL124 protein translation products
<400> 2
Met Glu Arg Asn Ser Leu Leu Val Cys Gln Leu Leu Cys Leu Val Ala
1 5 10 15
Arg Ala Ala Ala Thr Ser Thr Ala Gln Thr Thr Leu Pro Ser Thr Val
20 25 30
Asn Ser Thr Ala Thr Gly Val Thr Ser Asp Ser Tyr Gln Asn Thr Thr
35 40 45
Thr Gln Leu Pro Ala Ser Ser Ser Ala Ala Ala Leu Ser Leu Pro Asn
50 55 60
Ala Ser Ala Val Gln Ala Arg Ser Pro Ser Ser Phe Ser Asp Thr Tyr
65 70 75 80
Pro Thr Ala Thr Ala Leu Cys Gly Thr Leu Val Val Val Gly Ile Val
85 90 95
Leu Cys Leu Ser Leu Ala Ser Thr Val Arg Ser Lys Glu Leu Pro Ser
100 105 110
Asp His Glu Pro Leu Glu Ala Trp Glu Gln Gly Ser Asp Val Glu Ala
115 120 125
Pro Pro Leu Pro Glu Lys Ser Pro Cys Pro Glu His Val Pro Glu Ile
130 135 140
Arg Val Glu Ile Pro Arg Tyr Val
145 150
<210> 3
<211> 33
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<220>
<223>UL124 primers-F
<400> 3
cgcgcgaagc ttaacatagc gtgggatctc cac 33
<210> 4
<211> 39
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<220>
<223>UL124 primers-R
<400> 4
cggcgcggat ccatggaaag gaacagtctg ttagtctgt 39
Claims (7)
1. a kind of recombinant plasmid containing human cytomegalovirus UL124 genes, it is characterised in that:Containing UL124 genetic fragments,
In, the nucleotide sequence such as SEQ ID No of UL124 genetic fragments:Shown in 1.
2. a kind of genetic engineering bacterium containing human cytomegalovirus UL124 gene recombination plasmids, it is characterised in that:Conversion is had the right
It is required that the recombinant plasmid containing human cytomegalovirus UL124 genes described in 1.
3. the genetic engineering bacterium according to claim 2 containing human cytomegalovirus UL124 gene recombination plasmids, feature
It is:The genetic engineering bacterium is Escherichia coli.
4. the genetic engineering bacterium according to claim 2 containing human cytomegalovirus UL124 gene recombination plasmids, feature
It is:The genetic engineering bacterium is bacillus coli DH 5 alpha or BL21 (DE3).
5. the genetic engineering bacterium that claim 2~4 any one of them contains human cytomegalovirus UL124 gene recombination plasmids exists
Application in the preparation of UL124 recombinant proteins.
6. a kind of preparation method of UL124 recombinant proteins, it is characterised in that:Claim 2~4 any one of them is contained into someone
The genetic engineering bacterium of cytomegalovirus UL124 gene recombination plasmids passes through activation culture and fermented and cultured, adds derivant
IPTG carries out induced expression, obtains UL124 recombinant proteins.
7. the genetic engineering bacterium that claim 2~4 any one of them contains human cytomegalovirus UL124 gene recombination plasmids exists
Prepare the application in human cytomegalovirus UL124 protein polyclone antibodies.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810107622.2A CN108300729A (en) | 2018-02-02 | 2018-02-02 | Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810107622.2A CN108300729A (en) | 2018-02-02 | 2018-02-02 | Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108300729A true CN108300729A (en) | 2018-07-20 |
Family
ID=62851113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810107622.2A Pending CN108300729A (en) | 2018-02-02 | 2018-02-02 | Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108300729A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106591496A (en) * | 2017-01-19 | 2017-04-26 | 温州医科大学 | Human cytomegalovirus gene PCR detection chip covering whole genome |
-
2018
- 2018-02-02 CN CN201810107622.2A patent/CN108300729A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106591496A (en) * | 2017-01-19 | 2017-04-26 | 温州医科大学 | Human cytomegalovirus gene PCR detection chip covering whole genome |
Non-Patent Citations (5)
Title |
---|
JIANXIONG ZENG ET AL.: "Preparation of polyclonal antibody against human cytomegalovirus UL124 gene product", 《INTERNATIONAL JOURNAL OF SCIENCE》 * |
LINGLING HE ET AL.: "Preparation of polyclonal antibody against human cytomegalovirus UL146 gene product-α chemokine vCXC-1", 《INTERNATIONAL JOURNAL OF SCIENCE》 * |
TOMASEC, P. ET AL.: "Human herpesvirus 5 strain TB40/E clone Lisa, complete genome,GenBank: KF297339.1", 《GENBANK》 * |
毛有胜等: "人巨细胞病毒病毒体的组装研究新进展", 《微生物与感染》 * |
浮苗等: "人巨细胞病毒潜伏感染相关基因研究进展", 《中国病原生物学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108159409A (en) | A kind of 3 type Cap protein vaccine of pig circular ring virus and its preparation method and application | |
CN104725515B (en) | One species elastin polypeptide and Coxsackie Adenovirus Receptor fusion protein and its preparation method and application | |
CN111471089B (en) | Recombinant African swine fever virus CD2V subunit protein and preparation method and application thereof | |
CN112921005B (en) | Hybridoma cell strain, canine parvovirus VP2 protein monoclonal antibody produced by hybridoma cell strain and application of hybridoma cell strain | |
CN110157737A (en) | A kind of recombinant baculovirus for expressing African swine fever CD2V albumen in SF9 cell | |
CN108619503A (en) | A kind of pig circular ring virus genetic engineering subunit vaccine and the preparation method and application thereof | |
CN110317278A (en) | The fusion protein and its encoding gene of SVV and FMDV, expression vector, cell line, engineering bacteria and vaccine and application | |
CN108586618A (en) | A kind of preparation and application of pig epidemic diarrhea subunit vaccine | |
CN109609534A (en) | A kind of method and its application using 3 type ORF2 albumen of Bacillus coli expression pig circular ring virus | |
CN101845439A (en) | Method for using silkworm cultured cell to express antibacterial peptide Cecropin B | |
CN111217903A (en) | Recombinant human fibronectin III 1-C and preparation method and application thereof | |
CN103131676A (en) | Silkworm recombinant baculovirus showing recombinant human tumor necrosis factor receptor-Fc fusion protein gene, and preparing method and application thereof | |
CN108794638A (en) | A kind of recombinant bovine long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon | |
CN108300729A (en) | Recombinant plasmid, genetic engineering bacterium containing human cytomegalovirus UL124 genes and its application | |
CN106754981A (en) | A kind of method that utilization E. coli system prepares Goose Parvovirus sample particle | |
CN110927374A (en) | Colloidal gold test strip for detecting hepatitis E virus IgG antibody and preparation method thereof | |
CN110205323A (en) | Express the expressing gene, recombinant expression carrier, recombinant lactobacilli and its preparation method and application of 3 type interferon of pig | |
CN110257405A (en) | Mycoplasma bovis alcohol dehydrogenase gene and its coding albumen and application | |
CN111378017A (en) | Subunit F protein of peste des petits ruminants virus and preparation method and application thereof | |
CN105420174A (en) | Establishment of genetically engineered bacterium expressing recombined VEGF fusion protein | |
CN111378016B (en) | Subunit H protein of peste des petits ruminants virus, preparation method and application thereof | |
CN113667018A (en) | BR 2-anti p21Ras single-chain antibody fusion protein capable of entering tumor cells and preparation method thereof | |
CN113735943A (en) | Recombinant African swine fever virus p72 subunit protein, preparation method and application thereof | |
CN110257414A (en) | A kind of preparation method and its usage of mouse MIP3 α-endoglin Fc fusion protein | |
CN112961865A (en) | Recombinant trastuzumab expressed by using gene editing chicken bioreactor and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Hua Inventor after: Zeng Jianxiong Inventor before: Zhu Hua Inventor before: Zeng Jianxiong Inventor before: Liu Fenyong |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180720 |